-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FGF-1 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FGF-1 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FGF-1 in Parkinson's Disease Drug Details: FGF-1 is under development for the...
-
Product Insights
NewVenous Leg Ulcers (Crural Ulcer) – Drugs In Development, 2024
Empower your strategies with our Venous Leg Ulcers (Crural Ulcer) – Drugs In Development, 2024 report and make more profitable business decisions. Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles with pitting edema (fluid-filled tissue that temporarily holds the imprint of a finger when pressed); hemosiderosis (discoloration and darkening of the skin around the ulcer);...
-
Product Insights
NewCoronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024
Empower your strategies with our Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through...
-
Product Insights
NewPeripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially...
-
Product Insights
NewOcclusive Arterial Disease (OAD) – Drugs In Development, 2024
Empower your strategies with our Occlusive Arterial Disease (OAD) – Drugs In Development, 2024 report and make more profitable business decisions. Occlusive arterial disease (OAD), also known as peripheral arterial disease (PAD) or peripheral vascular disease (PVD), is characterized by the narrowing or blockage of arteries in the extremities, particularly the legs. This occurs due to atherosclerosis, a buildup of plaque made up of cholesterol, fats, calcium, and other substances within the arterial walls. Individuals with OAD may experience symptoms such...
-
Product Insights
NewPeripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024
Empower your strategies with our Peripheral Artery Occlusive Disease (PAOD) – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral artery occlusive disease (PAOD), also known as peripheral arterial disease (PAD), refers to a condition characterized by the narrowing or blockage of the arteries outside the heart, predominantly affecting the arteries in the legs. This narrowing occurs due to atherosclerosis, the buildup of plaque within the arterial walls, restricting blood flow to the limbs. Individuals with PAOD may...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FGF-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry FGF-1 Drug Details FGF-1 is under development for the treatment of Parkinson's disease, Alzheimer's...
-
Product Insights
Amyotrophic Lateral Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of amyotrophic lateral sclerosis include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss. The Amyotrophic Lateral Sclerosis pipeline market research report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type....
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...